RE:Change of operational policyI agree with you @Transperance, I think this is a very smart and bold move for the same reasons you have stated. Makes me speculate that they have a lot of confidence in the expectation for positive results and the value of this molecule.
Looking back at all the "this will be the year" moments... 2023 is shaping up to finally be that year: 1067 royalties kicking in, potential PET deal closing now that SBM has access to all Wanbang data and anti-aging trial results in the spring for a 3rd molecule with a total addressable market the largest yet. It has been the best news quarter in years.
Taking a step back - 30,000ft view... the journey has been long and a number of dissappointments for sure. As an investor a lot of woulda could moments. Having said that, the news of late is really quite incredible from such a micro biotech. A testiment about their tech platform and the sticktoitiveness of management. If I was in their position... the only way I could have done this is a strong belief in the science. I will also say, one thing management has always said is they are focused on the long term value of the company. They have never been a pump and dump group... maybe this year their plan will finally start to be reflected in the share price. Fingers crossed!!
Congrats to SBM management!
I will be holding my shares too.
GLTA